Pharmacokinetics of levofloxacin after single and multiple oral doses in patients undergoing intermittent haemodialysis

International Journal of Antimicrobial Agents

Volumn 32, Issue 1, 2008, Pages 46-49

  Tsaganos, Thomas ^a   Kouki, Pinelopi ^b   Digenis, Panagiotis ^b   Giamarellou, Helen ^a   Giamarellos Bourboulis, Evangelos J ^a   Kanellakopoulou, Kyriaki ^a  

^a NATIONAL AND KAPODISTRIAN UNIVERSITY OF ATHENS   (Greece)

^b KAT HOSPITAL   (Greece)

Author keywords

Haemodialysis; Levofloxacin; Pharmacokinetics; Renal failure

Indexed keywords

LEVOFLOXACIN;

ABSENCE OF SIDE EFFECTS; ADULT; AREA UNDER THE CURVE; ARTICLE; BLOOD SAMPLING; CLINICAL ARTICLE; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG RESEARCH; DRUG SAFETY; FLUORESCENCE; HEMODIALYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; KIDNEY FAILURE; MALE; PRIORITY JOURNAL; RENAL REPLACEMENT THERAPY;

ADMINISTRATION, ORAL; ADULT; AGED; AREA UNDER CURVE; BLOOD CHEMICAL ANALYSIS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; HALF-LIFE; HUMANS; KIDNEY FAILURE, CHRONIC; MALE; METABOLIC CLEARANCE RATE; MIDDLE AGED; OFLOXACIN; RENAL DIALYSIS; TIME FACTORS;

EID: 44949156232     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2008.02.011     Document Type: Article

References (21)

1. Dalhoff A., and Schmitz F.J. In vitro antibacterial activity and pharmacodynamics of new quinolones. Eur J Clin Microbiol Infect Dis 22 (2003) 203-221
2. Davis R., and Bryson H.M. Levofloxacin. A review of its antibacterial activity, pharmacokinetics and therapeutic efficacy. Drugs 47 (1994) 677-700
3. Hurst M., Lamb H.M., Scott L.J., and Figgitt D.P. Levofloxacin: an updated review of its use in the treatment of bacterial infections. Drugs 62 (2002) 2127-2167
4. Turnidge J. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Drugs 58 Suppl 2 (1999) 29-36
5. Rodvold K.A., and Neuhauser M. Pharmacokinetics and pharmacodynamics of fluoroquinolones. Pharmacotherapy 21 (2001) 233S-252S
6. Chien S.C., Chow A.T., Natarajan J., Williams R.R., Wong F.A., Rogge M.C., et al. Absence of age and gender effects on the pharmacokinetics of a single 500-milligram oral dose of levofloxacin in healthy subjects. Antimicrob Agents Chemother 41 (1997) 1562-1565
7. Nicolle L.E. Quinolones in the aged. Drugs 58 Suppl 2 (1999) 49-51
8. Liang H., Kays M.B., and Sowinski K.M. Separation of levofloxacin, ciprofloxacin, gatifloxacin, moxifloxacin, trovafloxacin and cinoxacin by high-performance liquid chromatography: application to levofloxacin determination in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 772 (2002) 53-63
9. Chien S.C., Wong F.A., Fowler C.L., Callery-D'Amico S.V., Williams R.R., Nayak R., et al. Double-blind evaluation of the safety and pharmacokinetics of multiple oral once-daily 750-milligram and 1-gram doses of levofloxacin in healthy volunteers. Antimicrob Agents Chemother 42 (1998) 885-888
10. Child J., Mortiboy D., Andrews J.M., Chow A.T., and Wise R. Open-label crossover study to determine pharmacokinetics and penetration of two dose regimens of levofloxacin into inflammatory fluid. Antimicrob Agents Chemother 39 (1995) 2749-2751
11. Smith I.L., and Schentag J.J. Noncompartmental determination of the steady-state volume of distribution during multiple dosing. J Pharm Sci 73 (1984) 281-282
12. Fillastre J.P., Leroy A., Moulin B., Dhib M., Borsa-Lebas F., and Humbert G. Pharmacokinetics of quinolones in renal insufficiency. J Antimicrob Chemother 26 Suppl B (1990) 51-60
13. Chien S.C., Rogge M.C., Gisclon L.G., Curtin C., Wong F., Natarajan J., et al. Pharmacokinetic profile of levofloxacin following once-daily 500-milligram oral or intravenous doses. Antimicrob Agents Chemother 41 (1997) 2256-2260
14. Chow A.T., Fowler C., Williams R.R., Morgan N., Kaminski S., and Natarajan J. Safety and pharmacokinetics of multiple 750-milligram doses of intravenous levofloxacin in healthy volunteers. Antimicrob Agents Chemother 45 (2001) 2122-2125
15. Lubasch A., Keller I., Borner K., Koeppe P., and Lode H. Comparative pharmacokinetics of ciprofloxacin, gatifloxacin, grepafloxacin, levofloxacin, trovafloxacin, and moxifloxacin after single oral administration in healthy volunteers. Antimicrob Agents Chemother 44 (2000) 2600-2603
16. Hansen E., Bucher M., Jakob W., Lemberger P., and Kees F. Pharmacokinetics of levofloxacin during continuous veno-venous hemofiltration. Intensive Care Med 27 (2001) 371-375
17. Traunmuller F., Thalhammer-Scherrer R., Locker G.J., Losert H., Schmid R., Staudinger T., et al. Single-dose pharmacokinetics of levofloxacin during continuous veno-venous haemofiltration in critically ill patients. J Antimicrob Chemother 47 (2001) 229-231
18. Czock D., Husig-Linde C., Langhoff A., Schopke T., Hafer C., de Groot K., et al. Pharmacokinetics of moxifloxacin and levofloxacin in intensive care unit patients who have acute renal failure and undergo extended daily dialysis. Clin J Am Soc Nephrol 1 (2006) 1263-1268
19. Guenter S.G., Iven H., Boos C., Bruch H.P., and Muhl E. Pharmacokinetics of levofloxacin during continuous venovenous hemodiafiltration and continuous venovenous hemofiltration in critically ill patients. Pharmacotherapy 22 (2002) 175-183
20. Sowinski K.M., Lucksiri A., Kays M.B., Scott M.K., Mueller B.A., and Hamburger R.J. Levofloxacin pharmacokinetics in ESRD and removal by the cellulose acetate high performance-210 hemodialyzer. Am J Kidney Dis 42 (2003) 342-349
21. Wakebe H., and Mitsuhashi S. Comparative in vitro activities of a new quinolone, OPC-17116, possessing potent activity against gram-positive bacteria. Antimicrob Agents Chemother 36 (1992) 2185-2191